This synergistic inhibitory treatment catalyses on the varied GSK-3β involvement in multiple signalling pathways to increase DNA damage and impair DNA repair, as well as alter the tumour microenvironment to reduce cell migration, cancer stemness, and metabolic pathways. This evidence concerns the gene GSK3B and neoplasm.